CN1197452A - 用于治疗动脉粥样硬化的氮杂环丁烷酮衍生物 - Google Patents
用于治疗动脉粥样硬化的氮杂环丁烷酮衍生物 Download PDFInfo
- Publication number
- CN1197452A CN1197452A CN96196661A CN96196661A CN1197452A CN 1197452 A CN1197452 A CN 1197452A CN 96196661 A CN96196661 A CN 96196661A CN 96196661 A CN96196661 A CN 96196661A CN 1197452 A CN1197452 A CN 1197452A
- Authority
- CN
- China
- Prior art keywords
- oxo
- azetidin
- benzyl
- diastereomer
- hexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9513442.5 | 1995-07-01 | ||
| GBGB9513442.5A GB9513442D0 (en) | 1995-07-01 | 1995-07-01 | Novel compounds |
| GBGB9515056.1A GB9515056D0 (en) | 1995-07-22 | 1995-07-22 | Novel compounds |
| GB9515056.1 | 1995-07-22 | ||
| GB9515206.2 | 1995-07-25 | ||
| GBGB9515206.2A GB9515206D0 (en) | 1995-07-25 | 1995-07-25 | Novel compounds |
| GB9516985.0 | 1995-08-18 | ||
| GBGB9516985.0A GB9516985D0 (en) | 1995-08-18 | 1995-08-18 | Novel compounds |
| GBGB9525132.8A GB9525132D0 (en) | 1995-12-08 | 1995-12-08 | Novel compounds |
| GB9525132.8 | 1995-12-08 | ||
| GB9608650.9 | 1996-04-26 | ||
| GBGB9608651.7A GB9608651D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| GB9608651.7 | 1996-04-26 | ||
| GBGB9608650.9A GB9608650D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1197452A true CN1197452A (zh) | 1998-10-28 |
Family
ID=27562921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96196661A Pending CN1197452A (zh) | 1995-07-01 | 1996-06-20 | 用于治疗动脉粥样硬化的氮杂环丁烷酮衍生物 |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0840725A1 (cs) |
| JP (1) | JP2002515852A (cs) |
| KR (1) | KR19990028630A (cs) |
| CN (1) | CN1197452A (cs) |
| AP (1) | AP728A (cs) |
| AU (1) | AU708032B2 (cs) |
| BG (1) | BG102214A (cs) |
| BR (1) | BR9609445A (cs) |
| CA (1) | CA2225627A1 (cs) |
| CZ (1) | CZ422197A3 (cs) |
| EA (1) | EA199800109A1 (cs) |
| HU (1) | HUP9901153A3 (cs) |
| IL (1) | IL122650A0 (cs) |
| MA (1) | MA23922A1 (cs) |
| MX (1) | MX9800186A (cs) |
| NO (1) | NO976158L (cs) |
| NZ (1) | NZ311684A (cs) |
| OA (1) | OA10648A (cs) |
| PE (1) | PE8998A1 (cs) |
| PL (1) | PL324240A1 (cs) |
| SK (1) | SK178497A3 (cs) |
| TR (1) | TR199701762T1 (cs) |
| WO (1) | WO1997002242A1 (cs) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0869943A1 (en) * | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
| GB9608649D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| IL126696A0 (en) * | 1996-04-26 | 1999-08-17 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis |
| DK1263740T3 (da) | 2000-02-16 | 2006-11-13 | Smithkline Beecham Plc | Pyrimidin-4-on-derivat som LDL-PLA2-inhibitor |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| KR101730290B1 (ko) | 2007-05-11 | 2017-04-25 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
| CN101687009A (zh) | 2007-05-11 | 2010-03-31 | 宾夕法尼亚大学理事会 | 治疗皮肤溃疡的方法 |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| KR101861883B1 (ko) | 2010-12-06 | 2018-05-28 | 글락소 그룹 리미티드 | Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물 |
| ES2847883T3 (es) | 2010-12-17 | 2021-08-04 | Glaxo Group Ltd | Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares |
| CN103619831B (zh) | 2011-06-27 | 2016-05-04 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
| CA2842965A1 (en) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
| AR087309A1 (es) | 2011-07-27 | 2014-03-12 | Glaxo Group Ltd | Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis |
| EP2948456A4 (en) | 2013-01-25 | 2016-09-14 | Glaxosmithkline Ip Dev Ltd | BICYCLIC PYRIMIDONE COMPOUNDS AS LP-PLA2 INHIBITORS |
| MX2015009633A (es) | 2013-01-25 | 2015-11-30 | Glaxosmithkline Ip Dev Ltd | Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. |
| US9296755B2 (en) | 2013-01-25 | 2016-03-29 | Glaxosmithkline Intellectual Property Development Limited | 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| EP4056571A4 (en) | 2019-11-09 | 2024-01-24 | Shanghai Simr Biotechnology Co., Ltd. | Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| WO2025015951A1 (zh) | 2023-07-17 | 2025-01-23 | 上海枢境生物科技有限公司 | 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
| IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
| GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| HUT77089A (hu) * | 1994-12-22 | 1998-03-02 | Smithkline Beecham Plc. | Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
-
1996
- 1996-06-20 CN CN96196661A patent/CN1197452A/zh active Pending
- 1996-06-20 KR KR1019970709952A patent/KR19990028630A/ko not_active Withdrawn
- 1996-06-20 JP JP50477297A patent/JP2002515852A/ja active Pending
- 1996-06-20 EP EP96922030A patent/EP0840725A1/en not_active Withdrawn
- 1996-06-20 WO PCT/EP1996/002765 patent/WO1997002242A1/en not_active Ceased
- 1996-06-20 AU AU63050/96A patent/AU708032B2/en not_active Ceased
- 1996-06-20 AP APAP/P/1997/001161A patent/AP728A/en active
- 1996-06-20 IL IL12265096A patent/IL122650A0/xx unknown
- 1996-06-20 CA CA002225627A patent/CA2225627A1/en not_active Abandoned
- 1996-06-20 PL PL96324240A patent/PL324240A1/xx unknown
- 1996-06-20 NZ NZ311684A patent/NZ311684A/xx unknown
- 1996-06-20 EA EA199800109A patent/EA199800109A1/ru unknown
- 1996-06-20 HU HU9901153A patent/HUP9901153A3/hu unknown
- 1996-06-20 BR BR9609445A patent/BR9609445A/pt unknown
- 1996-06-20 SK SK1784-97A patent/SK178497A3/sk unknown
- 1996-06-20 TR TR97/01762T patent/TR199701762T1/xx unknown
- 1996-06-20 CZ CZ974221A patent/CZ422197A3/cs unknown
- 1996-06-28 PE PE1996000496A patent/PE8998A1/es not_active Application Discontinuation
- 1996-06-28 MA MA24298A patent/MA23922A1/fr unknown
-
1997
- 1997-12-30 NO NO976158A patent/NO976158L/no unknown
- 1997-12-31 OA OA70172A patent/OA10648A/en unknown
-
1998
- 1998-01-07 MX MX9800186A patent/MX9800186A/es unknown
- 1998-01-28 BG BG102214A patent/BG102214A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK178497A3 (en) | 1998-07-08 |
| MX9800186A (es) | 1998-07-31 |
| OA10648A (en) | 2002-09-25 |
| HUP9901153A2 (hu) | 1999-08-30 |
| NZ311684A (en) | 2000-04-28 |
| PE8998A1 (es) | 1998-03-20 |
| TR199701762T1 (xx) | 1998-05-21 |
| KR19990028630A (ko) | 1999-04-15 |
| PL324240A1 (en) | 1998-05-11 |
| IL122650A0 (en) | 1998-08-16 |
| CA2225627A1 (en) | 1997-01-23 |
| WO1997002242A1 (en) | 1997-01-23 |
| AU708032B2 (en) | 1999-07-29 |
| NO976158D0 (no) | 1997-12-30 |
| BR9609445A (pt) | 1999-04-06 |
| JP2002515852A (ja) | 2002-05-28 |
| AU6305096A (en) | 1997-02-05 |
| BG102214A (en) | 1998-08-31 |
| HUP9901153A3 (en) | 1999-11-29 |
| AP728A (en) | 1999-01-29 |
| EA199800109A1 (ru) | 1998-10-29 |
| MA23922A1 (fr) | 1996-12-31 |
| EP0840725A1 (en) | 1998-05-13 |
| NO976158L (no) | 1998-02-25 |
| CZ422197A3 (cs) | 1998-06-17 |
| AP9701161A0 (en) | 1998-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1036006C (zh) | 抗菌素化合物碳代青霉烯 | |
| CN1095839C (zh) | 4,5－二芳基噁唑衍生物 | |
| CN1097052C (zh) | 脒吲哚衍生物及其盐的制备方法 | |
| CN1213025C (zh) | 硫代酰胺衍生物 | |
| CN1221529C (zh) | 取代的n－[(氨基亚氨基甲基或氨甲基)苯基]丙基酰胺 | |
| CN1175246A (zh) | 用于治疗动脉粥样硬化的取代的氮杂环丁－2－酮 | |
| CN1653047A (zh) | 抗炎症药物单环芳酰吡啶酮 | |
| CN1273128C (zh) | 取代的n－[(氨基亚氨基甲基或氨基甲基)苯基]丙基酰胺 | |
| CN1169791C (zh) | 新颖的乙酰胺衍生物和蛋白酶抑制剂 | |
| CN1037144A (zh) | 用作为消炎剂和抗退化剂的新的取代的氮氧杂丁酮 | |
| CN1196682C (zh) | 4－吡啶基－n－酰基－l－苯丙氨酸 | |
| CN1898199A (zh) | 用于治疗阿尔茨海默病的苯基酰胺和吡啶基酰胺类β－分泌酶抑制剂 | |
| CN1516690A (zh) | 杂环衍生物及医药品 | |
| CN1068815A (zh) | 用做抗炎及抗变性剂的新的取代氮杂环丁酮 | |
| CN1147250A (zh) | 作为前列腺素i2激动剂的萘衍生物 | |
| CN1571786A (zh) | 烷基醚衍生物或其盐 | |
| CN1079396C (zh) | 用作选择性凝血酶抑制剂的芳族脒衍生物 | |
| CN1798737A (zh) | 取代的4－苯基四氢异喹啉、其制备方法、其作为药物的用途和含有这类化合物的药物 | |
| CN1829519A (zh) | 二苯基取代的环烷烃类,含有它们的组合物和应用的方法 | |
| CN1400968A (zh) | 制备α－磺酰基异羟肟酸衍生物的方法 | |
| CN1011780B (zh) | 苯氧基乙酸衍生物的制备方法 | |
| CN1105799A (zh) | 作为基质金属蛋白酶抑制剂的喹诺酮衍生物 | |
| CN1819996A (zh) | 作为细胞色素p450抑制剂的亚萘基衍生物 | |
| CN1307560A (zh) | 脒基和胍基β－丙内酰胺类胰蛋白酶抑制剂 | |
| CN1437587A (zh) | 苯并氧氮杂庚因酮及其作为角鲨烯合成酶抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |